TriSalus Life Sciences, Inc.

TLSI

TriSalus Life Sciences, Inc.

TLSI

Insider Sentiment (TTM):

Last Purchase:2026-05-15Last Sale:2026-05-15Shares Purchased (TTM):845,069Shares Sold (TTM):18,532

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:20,188,464Shares Outstanding:51,539,682Institutional Ownership Pct.:39.17%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Derivative Financial Instruments Tranche Liability	-	-	-	-	-	-	-	-	-	-	0	0
Assets
Derivative Financial Instruments Series B3 Warrant…	-	-	-	-	-	-	-	-	-	-	0	0
Assets Current
Contingent Earnout Liability	-	-	-	-	-	-	-	-	-	-	-	9
Derivative Financial Instruments Warrant Liability	-	-	-	-	-	-	-	-	-	-	-	5
Cash And Cash Equivalents At Carrying Value	46	57	20	23	26	13	9	11	16	4	12	21
Accounts Receivable Net Current	6	5	7	5	6	5	5	5	5	4	4	3
Inventory Net	4	4	3	3	4	4	4	4	3	3	3	2
Prepaid Expense Current	3	3	2	2	2	2	3	4	3	2	3	3
Assets Current	60	68	32	33	38	25	21	24	28	13	21	29
Property Plant And Equipment Net	-	-	-	-	-	-	-	2	2	2	-	2
Property Plant And Equipment And Finance Lease Rig…	-	2	2	2	2	2	2	-	-	-	2	-
Operating Lease Right Of Use Asset	1	1	1	1	1	1	1	1	1	1	1	1
Finite Lived Intangible Assets Net	-	-	-	-	-	-	-	-	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	62	71	35	36	41	29	24	27	32	18	25	34
Liabilities And Stockhold…
Liabilities
Liabilities Current
Accounts Payable Trade Current	4	4	3	4	2	3	2	1	2	2	3	2
Accrued Liabilities Current	7	7	8	7	7	8	7	8	9	11	11	7
Other Liabilities Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	11	12	11	11	9	12	10	10	12	14	15	9
Long Term Debt Noncurrent	33	33	33	33	32	32	22	22	21	-	0	-
Business Combination Contingent Consideration Liab…	4	3	10	5	8	8	7	7	9	23	19	-
Derivative Liabilities Noncurrent	6	9	13	13	10	9	8	8	12	15	17	-
Liabilities	56	58	69	63	61	63	50	48	57	53	52	25
Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	345	342	297	294	279	256	254	249	242	227	222	221
Retained Earnings Accumulated Deficit	-338	-329	-331	-321	-298	-290	-280	-269	-266	-262	-250	-213
Stockholders Equity	7	13	-34	-27	-19	-34	-26	-20	-25	-36	-27	8
Liabilities And Stockholders Equity	62	71	35	36	41	29	24	27	32	18	25	34
Allowance For Doubtful Accounts Receivable Current	0	0	-	-	-	-	-	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Liquidation Preference	-	-	-	-	0	0	0	0	0	0	0	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	-
Preferred Stock Shares Issued	0	0	0	0	4	4	4	4	4	4	4	-
Preferred Stock Shares Outstanding	0	0	0	0	4	4	4	4	4	4	4	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	-
Common Stock Shares Issued	61	61	50	50	38	32	31	30	27	27	26	-
Shares Outstanding	61	61	50	50	38	32	31	30	27	27	26	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-30.48%	2.85%	-0.44%	-	-	-	-	-	-	-	-	-
2025	5.48%	-0.78%	-18.20%	36.71%	26.58%	29.86%	60.82%	38.95%	13.21%	-19.29%	-2.73%	-31.66%
2024	-30.67%	-38.13%	-41.00%	-14.57%	-22.26%	-31.49%	17.96%	25.19%	27.43%	-9.06%	-2.36%	-8.15%
2023	-	-	-	-	-	-	0.00%	119.75%	127.00%	-1.13%	-26.41%	-43.27%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.35	5.78	2.80	3.05	4.08	2.14	2.02	2.40	2.33	0.92	1.42	3.12
Quick Ratio	4.72	5.24	2.35	2.54	3.44	1.57	1.33	1.63	1.77	0.57	1.04	2.63
Working Capital	48.57M	56.35M	20.75M	22.42M	28.76M	13.34M	10.44M	13.89M	15.94M	-1.20M	6.18M	19.74M
Leverage & Debt
Debt to Equity	8.53	4.54	-2.04	-2.36	-3.13	-1.83	-1.93	-2.34	-2.24	-1.47	-1.91	3.02
Interest Coverage TTM	-5.23	-4.86	-4.86	-6.06	-6.40	-7.41	-11.70	-21.18	-59.49	-4,001.86	-3,404.69	-4,824.35
Debt Ratio	0.90	0.82	1.96	1.73	1.47	2.20	2.08	1.74	1.74	2.95	2.10	0.75
Efficiency & Turnover
Asset Turnover TTM	0.87	0.90	1.52	1.26	0.98	1.38	1.21	0.88	1.11	1.14	0.79	0.15
Days Sales Outstanding TTM	48.70	43.38	47.07	44.99	52.11	55.25	53.58	54.05	69.44	71.01	50.39	52.39
Receivables Turnover TTM	7.49	8.41	7.75	8.11	7.00	6.61	6.81	6.75	5.26	5.14	7.24	6.97
Per Share Metrics
Diluted EPS TTM	-0.99	-1.10	-1.84	-0.92	-0.94	-0.93	-1.19	-2.00	-2.20	-2.75	-6.32	-5.64
Free Cash Flow Per Share TTM	-0.38	-0.43	-0.54	-0.43	-0.78	-1.24	-1.63	-1.70	-2.33	-2.21	-5.45	-3.81
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	85.79%	85.07%	84.57%	84.04%	84.67%	85.60%	86.06%	87.10%	87.65%	86.74%	85.93%	83.16%
Operating Profit Margin TTM	-67.68%	-62.45%	-59.68%	-77.74%	-86.08%	-99.01%	-122.88%	-159.49%	-213.32%	-254.85%	-294.28%	-317.63%
Net Profit Margin TTM	-128.58%	-128.73%	-154.35%	-98.23%	-86.37%	-82.18%	-102.09%	-197.07%	-212.16%	-291.77%	-320.69%	-349.19%
Growth Metrics
Net Revenue Growth (1Y)	25.25%	39.64%	53.41%	49.51%	45.50%	46.20%	58.99%	26.47%	23.72%	42.92%	49.31%	442.03%
Net Income Growth (1Y)	86.47%	118.74%	131.95%	-25.47%	-40.77%	-58.82%	-49.39%	-28.63%	-34.78%	3.32%	18.69%	-289,299.47%
EPS Growth (1Y)	5.23%	21.07%	55.04%	-54.13%	-56.97%	-66.33%	-81.23%	-64.52%	-98.78%	-28.38%	-96.09%	-6,945.53%
Valuation Metrics
P/E TTM	-4.58	-3.57	-3.80	-5.07	-5.77	-5.96	-4.22	-2.31	-2.51	-3.55	-1.34	-0.91
P/B TTM	40.50	16.10	-7.81	-7.49	-9.23	-4.58	-4.90	-5.98	-5.22	-6.31	-2.93	8.13
P/S TTM	5.88	4.59	5.86	4.98	4.98	4.90	4.31	4.54	5.33	10.34	4.29	3.17
Market Cap	265.25M	206.16M	264.53M	200.22M	179.30M	157.47M	126.91M	122.17M	131.95M	227.40M	79.39M	67.45M
Enterprise Value	252.03M	182.68M	276.78M	209.94M	184.74M	175.82M	140.12M	132.21M	136.40M	223.08M	67.27M	45.81M
Calculated Values
Free Cash Flow TTM	-22.03M	-21.99M	-20.62M	-18.60M	-25.69M	-35.51M	-41.19M	-44.98M	-55.80M	-51.59M	-51.17M	-50.13M
Net Debt	-13.22M	-23.47M	12.26M	9.73M	5.43M	18.35M	13.21M	10.04M	4.46M	-4.32M	-12.13M	-21.63M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-15Purchase

Owner: Stansky, Michael P

Title: -

Shares: 410,000

Price/Share: $2.50

Value: $1,025,000.00

Shares Owned: 1,240,722

Relationship: Director

Ownership: Direct

2026-05-15Purchase

Owner: Wahlstrom, Mats

Title: -

Shares: 60,000

Price/Share: $2.53

Value: $151,800.00

Shares Owned: 147,555

Relationship: Director

Ownership: Direct

2026-05-15Purchase

Owner: Patience, David

Title: Chief Financial Officer

Shares: 7,100

Price/Share: $2.43

Value: $17,253.00

Shares Owned: 275,757

Relationship: Officer

Ownership: Direct

2026-05-15Purchase

Owner: Gordon, Gary B.

Title: -

Shares: 10,000

Price/Share: $2.46

Value: $24,600.00

Shares Owned: 72,510

Relationship: Director

Ownership: Direct

2026-05-15Purchase

Owner: Szela, Mary T

Title: CEO and President

Shares: 39,682

Price/Share: $2.59

Value: $102,776.38

Shares Owned: 1,065,215

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-15	Stansky, Michael P	Director	-	Direct	Purchase	410,000	2.50	$1,025,000.00	1,240,722	4
2026-05-15	Wahlstrom, Mats	Director	-	Direct	Purchase	60,000	2.53	$151,800.00	147,555	4
2026-05-15	Patience, David	Officer	Chief Financial Officer	Direct	Purchase	7,100	2.43	$17,253.00	275,757	4
2026-05-15	Gordon, Gary B.	Director	-	Direct	Purchase	10,000	2.46	$24,600.00	72,510	4
2026-05-15	Szela, Mary T	Director,Officer	CEO and President	Direct	Purchase	39,682	2.59	$102,776.38	1,065,215	4
2026-05-15	Marshak, Richard	Officer	Chief Commercial Officer	Direct	Sale	543	2.67	$1,449.81	125,101	4
2026-03-17	Szela, Mary T	Director,Officer	CEO and President	Direct	Sale	15,944	3.85	$61,384.40	752,987	4
2026-03-16	Marshak, Richard	Officer	Chief Commercial Officer	Direct	Sale	419	4.12	$1,726.28	110,397	4
2026-03-16	Stevens, Jennifer	Officer	Chief Regulatory Officer	Direct	Sale	774	4.12	$3,188.88	124,110	4
2026-03-16	Cox, Bryan F.	Officer	Chief of Research	Direct	Sale	579	4.12	$2,385.48	163,415	4
2026-03-16	Devlin, Jodi	Officer	Chief of Clinical Operations	Direct	Sale	273	4.12	$1,124.76	97,364	4
2026-02-23	Stansky, Michael P	Director	-	Direct	Purchase	243,900	4.10	$999,990.00	787,132	4
2026-02-23	Gordon, Gary B.	Director	-	Direct	Purchase	9,756	4.10	$39,999.60	9,756	4
2026-02-23	Patience, David	Officer	Chief Financial Officer	Direct	Purchase	3,657	4.10	$14,993.70	268,657	4
2026-02-23	Szela, Mary T	Director,Officer	CEO and President	Direct	Purchase	30,487	4.10	$124,996.70	773,289	4
2026-02-23	Valle, William	Director	-	Direct	Purchase	30,487	4.10	$124,996.70	30,487	4
2025-05-19	Devlin, Jodi	Officer	Chief of Clinical Operations	Direct	Sale	4,764	5.18	$24,677.52	52,764	4
2025-05-19	Marshak, Richard	Officer	Chief Commercial Officer	Direct	Sale	6,597	5.18	$34,172.46	69,101	4
2025-05-19	Cox, Bryan F.	Officer	Chief of Research	Direct	Sale	4,764	5.18	$24,677.52	119,415	4
2025-05-19	Stevens, Jennifer	Officer	Chief Regulatory Officer	Direct	Sale	8,704	5.18	$45,086.72	77,640	4
2025-02-05	Young, James Emmett	Officer	Chief Financial Officer	Indirect	Purchase	6,000	5.65	$33,900.00	30,000	4
2025-01-30	Szela, Mary T	Director,Officer	CEO AND PRESIDENT	Direct	Purchase	5,010	5.28	$26,452.80	444,259	4
2025-01-28	Murphy, Sean	Director,Officer	Chief Manuf, Strategy&Bus Dev.	Indirect	Purchase	15,000	5.17	$77,550.00	197,732	4
2025-01-28	Szela, Mary T	Director,Officer	CEO AND PRESIDENT	Direct	Purchase	4,716	5.12	$24,145.92	434,219	4
2025-01-27	Young, James Emmett	Officer	Chief Financial Officer	Indirect	Purchase	24,000	5.40	$129,600.00	24,000	4
2024-12-17	Frankenius, Equity Ab	TenPercentOwner	-	Direct	Purchase	62,972	3.97	$249,998.84	6,230,748	4
2024-12-10	Desai, Arjun Jj	Director	-	Direct	Sale	30,000	3.69	$110,700.00	247,127	4
2024-11-22	Wahlstrom, Mats	Director,TenPercentOwner	-	Direct	Purchase	5,000	4.55	$22,750.00	15,727	4
2024-11-21	Wahlstrom, Mats	Director,TenPercentOwner	-	Direct	Purchase	8,687	4.44	$38,570.28	10,727	4
2024-10-05	Cox, Bryan F.	Officer	CHIEF SCIENTIFIC & MANUFACT.	Direct	Sale	314	4.44	$1,394.16	86,382	4
2024-09-13	Szela, Mary T	Director,Officer	CEO AND PRESIDENT	Direct	Purchase	7,295	4.92	$35,891.40	384,677	4
2024-09-10	Szela, Mary T	Director,Officer	CEO AND PRESIDENT	Direct	Purchase	5,000	4.97	$24,850.00	369,862	4
2024-08-28	Martin, George Kelly	Director	-	Indirect	Sale	9	5.50	$49.50	247,176	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

39.17%

Inst. Shares: 20,188,464

Shares Outstanding: 51,539,682

2025-12-31

30.02%

Inst. Shares: 11,376,419

Shares Outstanding: 37,897,785

2025-09-30

22.11%

Inst. Shares: 9,519,897

Shares Outstanding: 43,057,632

2025-06-30

25.46%

Inst. Shares: 8,377,164

Shares Outstanding: 32,899,297

2025-03-31

10.15%

Inst. Shares: 2,895,234

Shares Outstanding: 28,527,453

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	20,188,464	51,539,682	39.17%
2025-12-31	11,376,419	37,897,785	30.02%
2025-09-30	9,519,897	43,057,632	22.11%
2025-06-30	8,377,164	32,899,297	25.46%
2025-03-31	2,895,234	28,527,453	10.15%
2024-12-31	1,880,196	25,331,753	7.42%
2024-09-30	1,670,390	26,501,597	6.30%
2024-06-30	1,307,561	23,903,659	5.47%
2024-03-31	594,529	23,323,045	2.55%
2023-12-31	616,101	9,395,748	6.56%
2023-09-30	136,575	13,173,422	1.04%
2023-06-30	751,967	446,287	168.49%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

TriSalus Life Sciences, Inc. (TLSI) — SEC Financial Statements & Analysis

TriSalus Life Sciences, Inc. (TLSI) is a surgical & medical instruments & apparatus company, incorporated in DE. TriSalus Life Sciences, Inc. trades on Nasdaq as: TLSI, TLSIW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), TriSalus Life Sciences, Inc. reported a 25.25% year-over-year revenue growth, a Gross Profit Margin of 85.79% (TTM), a Debt-to-Equity ratio of 8.53x, a Price-to-Sales (P/S) ratio of 5.88x (TTM), a Price-to-Book (P/B) ratio of 40.50x (TTM), at a market cap of $265.25M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 25.25%
Gross Profit Margin TTM: 85.79%
Debt To Equity: 8.53x
P/S TTM: 5.88x
P/B TTM: 40.50x
Market Cap: $265.25M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is TriSalus Life Sciences, Inc. in?

TriSalus Life Sciences, Inc. (TLSI) operates in the Surgical & Medical Instruments & Apparatus industry.

What is TLSI's market cap?

TriSalus Life Sciences, Inc. (TLSI) has a market capitalization of $265.25M as of 2026-06-30.

What exchange does TLSI trade on?

TriSalus Life Sciences, Inc. (TLSI) trades on the Nasdaq.

Where is TriSalus Life Sciences, Inc. incorporated?

TriSalus Life Sciences, Inc. is incorporated in DE.